"A seemingly beneficial $50 monthly price cap for GLP-1 medications under Medicare’s new Bridge program is inadvertently excluding nearly six million beneficiaries who have a qualifying diagnosis for these drugs, forcing them onto more expensive Part D plans."
This critical design flaw within the Medicare GLP-1 Bridge, intended to offer affordable access to weight-loss medications, is now resulting in significant financial burdens for many, despite having diagnoses that these powerful drugs are approved to treat, such as type 2 diabetes and obstructive sleep apnea. The exclusion stems from a rule stipulating that the discounted price only applies when the GLP-1 is prescribed solely for weight loss. Those with an FDA-approved indication for the drug are instead redirected to their standard Part D prescription drug plans, where out-of-pocket costs can escalate to hundreds of dollars per month, creating a stark affordability gap for individuals on fixed retirement incomes.
The Medicare GLP-1 Bridge, an 18-month pilot program launched in July, aimed to address a long-standing statutory limitation: Medicare’s inability to cover drugs prescribed solely for weight loss. The program was designed to fill this gap by offering a $50 monthly copay for specific GLP-1 medications – Wegovy, the KwikPen formulation of Zepbound, and the oral medication Foundayo – for eligible beneficiaries. Eligibility is generally tied to a body mass index (BMI) of 35 or higher, or a BMI between 27 and 34 coupled with certain health conditions like prediabetes or cardiovascular disease. However, the program’s exclusionary clause has come to light, revealing a significant disconnect between its intended purpose and its practical impact on beneficiaries with pre-existing conditions.
Jeff La Marca, a 68-year-old retired professor from Basking Ridge, New Jersey, exemplifies the consequences of this design. After receiving a Zepbound prescription in January and facing a prohibitive $750 monthly cost, he applied for the Bridge program. His application was denied. La Marca has severe obstructive sleep apnea, a diagnosis that, according to the program’s rules, disqualifies him from the $50 Bridge price. Despite his BMI of 42, a history of quadruple heart bypass surgery, stroke risk, and prediabetes, he found himself ineligible for the discounted rate. "And yet I can’t get it. I’m livid," La Marca told KFF Health News, expressing his frustration with a system that offers a potential solution but locks him out due to a concurrent medical condition.
Juliette Cubanski, director of the Program on Medicare Policy at KFF, explained the underlying logic: "The Bridge was designed to target those people who can’t get GLP-1 coverage through Part D." This intention, however, clashes with the reality faced by beneficiaries like La Marca, for whom coverage exists on paper but affordability remains an insurmountable barrier. The rule effectively bifurcates beneficiaries with identical weight and prescription needs, leading to vastly different financial outcomes based solely on the diagnoses listed in their medical records.
The practical implications for individuals living on fixed retirement incomes are severe. Two Medicare beneficiaries with the same BMI and the same prescription for a GLP-1 drug could end up paying $50 per month or several hundred dollars, a discrepancy determined by whether their medical charts include a diagnosis for which the drug is FDA-approved. This creates a system where essential medication access is dictated by the presence of other co-occurring conditions, rather than solely by the need for weight management or the treatment of associated health issues.
Physicians on the front lines are witnessing this disparity firsthand. Dr. Taylor Lacy, a primary care physician at Sunflower Medical Group in Roeland Park, Kansas, noted, "Coverage doesn’t always mean affordable." She described the arduous journey many Medicare patients undertake, navigating prior authorization, enduring months of step therapy with less effective alternatives, only to arrive at the pharmacy counter facing copays ranging from $200 to $600 per month or more. Dr. Lacy observed that the Bridge program, in its current form, leaves behind patients who often have the greatest medical needs and are least able to absorb such high costs.
Published analyses of GLP-1 coverage within Medicare have consistently highlighted rising out-of-pocket expenses and near-universal prior authorization requirements. Chris Bond, a spokesperson for the insurance trade group AHIP, pointed to manufacturer pricing as the primary driver of these high costs, stating, "which they alone set and they alone can lower." While the Centers for Medicare & Medicaid Services (CMS) reports that the demonstration is progressing smoothly, with most prior authorization requests processed in under 12 hours and thousands of beneficiaries obtaining medications, this positive operational feedback does not alleviate the fundamental affordability issue for those excluded by the diagnosis clause.
The financial scope of the Bridge program is substantial. Cubanski projected that if a quarter of the estimated 3.8 million eligible beneficiaries enroll and remain on treatment for the full 18 months, the cost to Medicare could approach $3.3 billion. If three-quarters enroll, the cost could soar to $10 billion. Expanding eligibility to the additional 5.9 million overweight beneficiaries already covered by Part D for GLP-1s would further escalate these figures by billions. The federal government has yet to release its own comprehensive cost estimate for the program.
This exclusion marks a significant development since MedicalDaily’s earlier report in July on the launch of the Medicare GLP-1 Bridge. The initial coverage detailed who qualified and the mechanics of the $50 copay, noting exclusions for beneficiaries already receiving GLP-1s through Part D and that the copay did not count towards the Part D out-of-pocket cap. The newly uncovered diagnosis-based routing and its sheer scale – affecting an estimated 5.9 million beneficiaries – represent a critical expansion of understanding the program’s limitations. The earlier reporting did not establish that holding an FDA-approved indication for these drugs was itself a disqualifier, nor did it quantify the substantial number of beneficiaries falling into this category. The current reporting adds a documented denial, provides the CMS perspective on processing times, and includes independent cost projections, painting a more complete picture of the program’s impact.
The broader structural concern that MedicalDaily previously raised remains pertinent: the Bridge is a temporary, 18-month pilot. The development of a permanent replacement model has been delayed, leaving beneficiaries who initiate treatment now uncertain about future coverage and cost. This uncertainty adds another layer of stress for individuals relying on these medications for their health and well-being.
For beneficiaries caught in this coverage gap, several steps can be taken. It is crucial that no one stops or starts a prescription without consulting their clinician, as GLP-1 medications require medical supervision, and abrupt changes can pose health risks. If a beneficiary has been denied or anticipates denial, they should first ask their prescriber to clarify the exact diagnosis that triggered the routing back to Part D, as denial notifications may not always specify this. Next, they should formally request their Part D plan’s formulary and tier placement in writing to ascertain the actual copay before assuming it is unaffordable. If the drug is covered but the cost-sharing remains prohibitive, beneficiaries have the right to inquire about the plan’s exception and appeals process, which is a formal entitlement under Part D, not a discretionary offer.
Additionally, beneficiaries can explore manufacturer patient assistance programs. However, eligibility rules for individuals with Medicare coverage can vary, and these should be confirmed directly with the manufacturers. State Health Insurance Assistance Program (SHIP) counselors offer free consultations to review plan options. The Medicare open enrollment period, running from October 15 to December 7, presents a critical window for beneficiaries to compare how different plans will cover these medications in the upcoming year.
Achieving permanent Medicare coverage for weight-loss drugs would necessitate legislative action from Congress. The future trajectory of the GLP-1 Bridge program hinges on potential modifications by CMS to narrow or clarify the diagnosis exclusion, and whether a successor program is finalized before the current pilot expires. These developments will be critical to monitor for beneficiaries seeking long-term access to these transformative medications.
